Outcomes of Autologous Hematopoietic Cell Transplantation Compared to Chemotherapy Consolidation Alone for Non-High Risk Acute Myeloid Leukemia in First Complete Remission in a Minority-Rich Inner-City Cohort with Limited Access to Allografts
ConclusionIn this inner-city non-high risk AML cohort, autoHCT provided OS and RFS benefit compared to chemotherapy alone. AutoHCT may constitute a valuable option for ethnic/racial minorities affected by significant barriers to alloHCT, while integration of measurable residual disease can help select patients more likely to benefit.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Bone Graft | Cancer & Oncology | Chemotherapy | Dermatology | Leukemia | Lymphoma | Myeloma | Transplants | USA Health